Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Total Non-current Assets
All assets not expected to be converted to cash within one year.
Sagimet Biosciences Inc.NASDAQ: SGMT
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 61.0% from a year ago
Total non-current assets stood at $39K at the end of Q1 FY2026, down 61.0% from a year earlier and down 50.0% from the prior quarter. Over 3 fiscal years it compounded at -31.2% a year.
Context
- Total non-current assets amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -61.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 78K USD
- Year-over-year change
- -99.0%
- 4-year CAGR
- -32.2%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 78K | -99.0% |
| FY2024 | 2024-12-31 | 7.49M | +10153.4% |
| FY2023 | 2023-12-31 | 73K | -69.5% |
| FY2022 | 2022-12-31 | 239K | -35.2% |
| FY2021 | 2021-12-31 | 369K | — |
Total Non-current Assets vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 total non-current assets of $39K is the lowest of the 11 companies compared; the peer median is $31.32M.
- Its year-over-year change of -61.0% is the lowest of 11, against a peer median of -17.3%.
- Total non-current assets amounts to 0.0% of total assets for SGMT, versus a peer median of 13.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $53.4B | +427956.3% | +60.0% | 24.9% | |
| Mar 2026 | $72.34M | -33.0% | +12.5% | 33.0% | |
| Mar 2026 | $68.65M | -17.6% | +19.0% | 20.5% | |
| Mar 2026 | $46.96M | -47.1% | -1.0% | 42.5% | |
| Mar 2026 | $34.1M | +2.5% | -13.3% | 15.4% | |
| Mar 2026 | $28.53M | -46.2% | -14.2% | 11.6% | |
| Mar 2026 | $3.88M | -38.0% | -9.9% | 1.5% | |
| Mar 2026 | $2.9M | -17.0% | -14.3% | 1.2% | |
| Mar 2026 | $2.04M | -13.3% | -10.4% | 6.2% | |
ZURAZura Bio Limited | Mar 2026 | $1.64M | +103.6% | -22.3% | 0.7% |
SGMTSagimet Biosciences Inc. | Mar 2026 | $39K | -61.0% | -31.2% | 0.0% |
| Peer median (excluding SGMT) | $31.32M | -17.3% | -10.2% | 13.5% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.